{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:55:47Z","timestamp":1790034947986,"version":"4.0.1"},"reference-count":142,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012259","name":"Major Discipline Academic and Technical Leaders Training Program of Jiangxi Province","doi-asserted-by":"publisher","award":["20225BCJ22001"],"award-info":[{"award-number":["20225BCJ22001"]}],"id":[{"id":"10.13039\/501100012259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Acute myeloid leukemia (AML) remains a difficult disease to treat, especially in patients with relapsed or refractory disease. While chimeric antigen receptor T cell (CAR-T) therapy has transformed the treatment landscape of several B-cell malignancies, its clinical efficacy in AML has been substantially more limited. This limited efficacy reflects not only challenges in CAR design, but also the complex biological and immunological barriers inherent to AML. Insufficient target specificity, pronounced leukemic heterogeneity, and an immunosuppressive bone marrow microenvironment collectively impair CAR-T cell recognition, persistence, and effector function, thereby restricting both therapeutic efficacy and safety. In this review, we discuss these major barriers and summarize emerging engineering strategies developed to address them, including approaches to improve targeting precision, reinforce CAR-T cell functional fitness, and remodel the suppressive immune niche. Together, these insights may help clarify the key barriers to effective CAR-T therapy in AML and inform future strategies for its optimization.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1837609","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:04:45Z","timestamp":1784095485000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunological barriers and engineering strategies for CAR-T cell therapy in acute myeloid leukemia"],"prefix":"10.3389","volume":"17","author":[{"given":"Ya","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Provincial Key Laboratory of Hematological Diseases (2024SSY06052)","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Provincial Key Laboratory of Hematological Diseases (2024SSY06052)","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Provincial Key Laboratory of Hematological Diseases (2024SSY06052)","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Provincial Key Laboratory of Hematological Diseases (2024SSY06052)","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: Current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27584","article-title":"Treatment of relapsed\/refractory aml-novel treatment options including immunotherapy","volume":"100","author":"Moore","year":"2025","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: Current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"Car-t cell therapy for cancer: Current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-025-01701-6","article-title":"Insights into next-generation immunotherapy designs and tools: Molecular mechanisms and therapeutic prospects","volume":"18","author":"Qin","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of car-t cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the car t cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous t-lymphocytes genetically retargeted against carbonic anhydrase ix: First clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified t cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing t cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0417-9","article-title":"Constitutively active myd88\/cd40 costimulation enhances expansion and efficacy of chimeric antigen receptor t cells targeting hematological Malignancies","volume":"33","author":"Collinson-Pautz","year":"2019","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of car t-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"Car t cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123586","article-title":"Immunomodulatory effects of il-2 and il-15; implications for cancer immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a jak-stat signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","article-title":"Target selection for car-t therapy","volume":"12","author":"Wei","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative car targeting to selectively eliminate aml and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1186\/s12967-025-07151-5","article-title":"Car-t and car-nk cell therapies in aml: Breaking barriers and charting the future","volume":"23","author":"Wu","year":"2025","journal-title":"J Transl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of cd33 and cd123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000845","article-title":"41bb-based and cd28-based cd123-redirected t-cells ablate human normal hematopoiesis in vivo","volume":"8","author":"Baroni","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of sl-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70120","article-title":"Challenges and solutions to implementation of chimeric antigen receptor therapies in acute myeloid leukemia","volume":"116","author":"Maheswaran","year":"2026","journal-title":"Eur J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0818-9","article-title":"Anti-human cd117 car t-cells efficiently eliminate healthy and Malignant cd117-expressing hematopoietic cells","volume":"34","author":"Myburgh","year":"2020","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.240747","article-title":"Maintenance therapy for flt3-itd-mutated acute myeloid leukemia","volume":"106","author":"Burchert","year":"2021","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous cd33-car-t cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of cll-1 car-t cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","article-title":"Unveiling the potential of cll-1: A promising target for aml therapy","volume":"13","author":"Soleimani Samarkhazan","year":"2025","journal-title":"biomark Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-04-1659","article-title":"C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.10.003","article-title":"Prognostic and therapeutic role of clec12a in acute myeloid leukemia","volume":"34","author":"Morsink","year":"2019","journal-title":"Blood Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in aml","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0553-5","article-title":"Car-t cells targeting cll-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20152008","article-title":"Cd70\/cd27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00774.x","article-title":"Timing and tuning of cd27-cd70 interactions: The impact of signal strength in setting the balance between adaptive responses and immunopathology","volume":"229","author":"Nolte","year":"2009","journal-title":"Immunol Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1093750","article-title":"Preclinical evaluation of cd70-specific car t cells targeting acute myeloid leukemia","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-493361","article-title":"Cd44v6-targeted t cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1043","article-title":"Cd44v6 chimeric antigen receptor t cell specificity towards aml with flt3 or dnmt3a mutations","volume":"12","author":"Tang","year":"2022","journal-title":"Clin Transl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007059","article-title":"Cd38 as a pan-hematologic target for chimeric antigen receptor t cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100551108","article-title":"Prospective separation of normal and leukemic stem cells based on differential expression of tim3, a human acute myeloid leukemia stem cell marker","volume":"108","author":"Jan","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.Bcd-20-0208","article-title":"Not-gated cd93 car t cells effectively target aml with minimized endothelial cross-reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"B43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"Cd38-directed car-t cell therapy: A novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017935","article-title":"Selecting cd7- t cells for car t-cell therapy","volume":"140","author":"Themeli","year":"2022","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102148","article-title":"Cd97-directed car-t cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models","volume":"6","author":"Shang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified cd7-targeting allogeneic car-t cell therapy with enhanced efficacy for relapsed\/refractory cd7-positive hematological Malignancies: A phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-15-0098","article-title":"Nkg2d receptor and its ligands in host defense","volume":"3","author":"Lanier","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101311","article-title":"Nkg2d ligand expression in aml increases in response to hdac inhibitor valproic acid and contributes to allorecognition by nk-cell lines with single kir-hla class I specificities","volume":"111","author":"Diermayr","year":"2008","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(22)00378-7","article-title":"Cyad-01, an autologous nkg2d-based car t-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (think): Haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180147","article-title":"Il1rap potentiates multiple oncogenic signaling pathways in aml","volume":"215","author":"Mitchell","year":"2018","journal-title":"J Exp Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004222","article-title":"Chimeric antigen receptor T-cells targeting Il-1rap: A promising new cellular immunotherapy to treat acute myeloid leukemia","volume":"10","author":"Trad","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02351-2","article-title":"Rational combinatorial targeting by adapter Car-T-cells (Adcar-T) prevents antigen escape in acute myeloid leukemia","volume":"38","author":"Atar","year":"2024","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013304","article-title":"Validation of the revised 2022 European Leukemianet risk stratification in adult patients with acute myeloid leukemia","volume":"9","author":"Ruhnke","year":"2025","journal-title":"Blood Adv"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","article-title":"Strategies to overcome tumour relapse caused by antigen escape after Car T therapy","volume":"24","author":"Lu","year":"2025","journal-title":"Mol Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in Car-T cell therapy: Mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s10020-025-01085-w","article-title":"Single cell Rna sequencing improves the next generation of approaches to Aml treatment: Challenges and perspectives","volume":"31","author":"Khosroabadi","year":"2025","journal-title":"Mol Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00729-2","article-title":"Advancing Car T cell therapy through the use of multidimensional omics data","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01684-0","article-title":"Single-cell transcriptomic atlas-guided development of Car-T cells for the treatment of acute myeloid leukemia","volume":"41","author":"Gottschlich","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of Car T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1038\/s41467-023-41994-0","article-title":"Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia","volume":"14","author":"Mumme","year":"2023","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018092","article-title":"Metabolism in acute myeloid leukemia: Mechanistic insights and therapeutic targets","volume":"141","author":"Mishra","year":"2023","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1695244","article-title":"Mitochondrial priming in therapy-induced senescence: Implications for Car-T\/Nk immunosenolytic therapy","volume":"16","author":"Menendez","year":"2025","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105063","article-title":"Oxidative stress in Car-T cell therapy: Mechanistic insights and redox-targeted interventions","volume":"217","author":"Xu","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3016","article-title":"Metabolic challenges and interventions in Car T cell therapy","volume":"8","author":"Peng","year":"2023","journal-title":"Sci Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1627161","article-title":"Immunosuppressive cells in acute myeloid leukemia: Mechanisms and therapeutic target","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00262","article-title":"A bump in the road: How the hostile Aml microenvironment affects Car T cell therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nature12988","article-title":"In vivo discovery of immunotherapy targets in the tumour microenvironment","volume":"506","author":"Zhou","year":"2014","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13324","article-title":"Cd155, an onco-immunologic molecule in human tumors","volume":"108","author":"Gao","year":"2017","journal-title":"Cancer Sci"},{"key":"B73","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s40164-025-00726-4","article-title":"Emerging strategies in Car-T cell therapy for acute myeloid leukemia: Overcoming heterogeneity and improving safety through dual-antigen targeting","volume":"14","author":"Oca\u00f1a-Cara","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902661","article-title":"Mechanism of T cell tolerance induced by myeloid-derived suppressor cells","volume":"184","author":"Nagaraj","year":"2010","journal-title":"J Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: How Aml and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011768","article-title":"Acquisition of an immunosuppressive microenvironment after anti-Cd19 Car T-cell therapy is associated with T-cell dysfunction and resistance","volume":"13","author":"Ponzo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.12.025","article-title":"Dr5 Car-T cells target melanoma and suppress Mdscs with minimal toxicity","volume":"34","author":"Wang","year":"2026","journal-title":"Mol Ther"},{"key":"B78","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40425-018-0432-9","article-title":"Cd33\/Cd3-bispecific T-cell engaging (Bite\u00ae) antibody construct targets monocytic Aml myeloid-derived suppressor cells","volume":"6","author":"Jitschin","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099226","article-title":"Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity","volume":"111","author":"Movahedi","year":"2008","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of Car-T therapy in hematological Malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02227","article-title":"Acute myeloid leukemia cells express Icos ligand to promote the expansion of regulatory T cells","volume":"9","author":"Han","year":"2018","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036863","article-title":"Modulation of tryptophan catabolism by human leukemic cells results in the conversion of Cd25- into Cd25+ T regulatory cells","volume":"109","author":"Curti","year":"2007","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01746-8","article-title":"Targeting Jmjd1c to selectively disrupt tumor T(Reg) cell fitness enhances antitumor immunity","volume":"25","author":"Long","year":"2024","journal-title":"Nat Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143180","article-title":"Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a growth factor independence 1 dependent manner","volume":"101","author":"Al-Matary","year":"2016","journal-title":"Haematologica"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004400","article-title":"Pd-L1 blockade restores Car T cell activity through Ifn-\u0393-regulation of Cd163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"Car T cell-induced cytokine release syndrome is mediated by macrophages and abated by Il-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2023.01.002","article-title":"Metabolism and epigenetics at the heart of T cell function","volume":"44","author":"Soriano-Baguet","year":"2023","journal-title":"Trends Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1688995","article-title":"Metabolic reprogramming of Car T cells: A new frontier in cancer immunotherapy","volume":"16","author":"Frlic","year":"2025","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2024.02.003","article-title":"From suppressor to enhancer: Il-10's alternative role in Car-T cell therapies against solid tumors","volume":"31","author":"Huang","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001797","article-title":"Lingering effects of chemotherapy on mature T cells impair proliferation","volume":"4","author":"Das","year":"2020","journal-title":"Blood Adv"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117999","article-title":"The hypoxia signaling pathway in the development of acute myeloid leukemia","volume":"186","author":"Yang","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019961","article-title":"Escape from T-cell-targeting immunotherapies in acute myeloid leukemia","volume":"143","author":"Vadakekolathu","year":"2024","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006287","article-title":"Inhibition of lactate transport by Mct-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell Malignancies","volume":"11","author":"Lopez","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (Ido) inhibits Cd19-Car T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12967-025-06276-x","article-title":"Ido1 inhibition enhances Cldn18.2-Car-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment","volume":"23","author":"Wu","year":"2025","journal-title":"J Transl Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004500","article-title":"Metabolic engineering against the arginine microenvironment enhances Car-T cell proliferation and therapeutic activity","volume":"136","author":"Fultang","year":"2020","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32028","article-title":"Targeting the arginine metabolic brake enhances immunotherapy for leukaemia","volume":"145","author":"Mussai","year":"2019","journal-title":"Int J Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cmet.2023.12.010","article-title":"Mitochondrial isocitrate dehydrogenase impedes Car T cell function by restraining antioxidant metabolism and histone acetylation","volume":"36","author":"Si","year":"2024","journal-title":"Cell Metab"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19001","article-title":"Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas","volume":"203","author":"Gao","year":"2023","journal-title":"Br J Haematol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1493329","article-title":"Multi-targeted, not gated Car-T cells as a strategy to protect normal lineages for blood cancer therapy","volume":"16","author":"DiAndreth","year":"2025","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"Car immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.cell.2022.03.023","article-title":"Modular design of synthetic receptors for programmed gene regulation in cell therapies","volume":"185","author":"Zhu","year":"2022","journal-title":"Cell"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02409-1","article-title":"Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with car t-cells","volume":"38","author":"Volta","year":"2024","journal-title":"Leukemia"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125428","article-title":"The problem of molecular target choice for car-t cells in acute myeloid leukemia therapy","volume":"26","author":"Maiorova","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2025.102524","article-title":"Novel approaches to car t cell target identification in acute myeloid leukemia","volume":"82","author":"Hoffmann","year":"2025","journal-title":"Curr Opin Pharmacol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.147","article-title":"Targeting flt3 by chimeric antigen receptor t cells for the treatment of acute myeloid leukemia","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021054","article-title":"A dual-receptor t-cell platform with ab-tcr and costimulatory receptor achieves specificity and potency against aml","volume":"143","author":"Dao","year":"2024","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014105","article-title":"Current developments in t-cell receptor therapy for acute myeloid leukemia","volume":"9","author":"Gore","year":"2025","journal-title":"Blood Adv"},{"key":"B109","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-023-01494-6","article-title":"Advances in single-cell rna sequencing and its applications in cancer research","volume":"16","author":"Huang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40164-025-00651-6","article-title":"Breakthroughs of car t-cell therapy in acute myeloid leukemia: updates from ash 2024","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02767-4","article-title":"Downregulation of mica\/micb improves cell persistence and clinical activity of nkg2dl car t-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia","volume":"39","author":"Pollyea","year":"2025","journal-title":"Leukemia"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003588","article-title":"Crispr\/cas9-engineered universal cd123\/b7-h3 tandem car-t cell for the treatment of acute myeloid leukemia","volume":"139","author":"Li","year":"2026","journal-title":"Chin Med J (Engl)"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018168","article-title":"Flt3-directed bite molecules versus car t cells in aml: co-stimulatory signals mitigate t-cell exhaustion","volume":"10","author":"Rohrbacher","year":"2026","journal-title":"Blood Adv"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101826","article-title":"Il-21\/il-21r signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and car t cell therapy","volume":"5","author":"Rubino","year":"2024","journal-title":"Cell Rep Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s42003-026-09528-8","article-title":"Il-15 overexpression promotes memory program and anti-tumor activity of cd64 car t cells in a preclinical aml model","volume":"9","author":"Shan","year":"2026","journal-title":"Commun Biol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029532","article-title":"Cd371-targeted car t cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia","volume":"146","author":"Geyer","year":"2025","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.1038\/s41467-024-50485-9","article-title":"C-jun overexpressing car-t cells in acute myeloid leukemia: preclinical characterization and phase i trial","volume":"15","author":"Zuo","year":"2024","journal-title":"Nat Commun"},{"key":"B118","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3892\/mmr.2021.11847","article-title":"Cytotoxic effect of cll-1 car-t cell immunotherapy with pd-1 silencing on relapsed\/refractory acute myeloid leukemia","volume":"23","author":"Lin","year":"2021","journal-title":"Mol Med Rep"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2023.2248826","article-title":"Car-t cells dual-target cd123 and nkg2dls to eradicate aml cells and selectively target immunosuppressive cells","volume":"12","author":"Jin","year":"2023","journal-title":"Oncoimmunology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40364-024-00667-w","article-title":"Brd4 inhibitor reduces exhaustion and blocks terminal differentiation in car-t cells by modulating batf and egr1","volume":"12","author":"Sui","year":"2024","journal-title":"biomark Res"},{"key":"B121","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-cd123 car t cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat Commun"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006857","article-title":"Valproic acid increases car t cell cytotoxicity against acute myeloid leukemia","volume":"11","author":"Wen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and anti-leukemic activity of cd123-car t cells in pediatric patients with aml: preliminary results from a phase 1 trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168877","article-title":"Phase 1 dose escalation study of the rapidly switchable universal car-t therapy unicar-t-cd123 in relapsed\/refractory aml","volume":"140","author":"Ehninger","year":"2022","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal car-t platform with unicar-t-cd123 in relapsed\/refractory aml","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6074.Tumimm18-pr14","article-title":"Abstract pr14: cd123car displays clinical activity in relapsed\/refractory (r\/r) acute myeloid leukemia (aml) and blastic plasmacytoid dendritic cell neoplasm (bpdcn): safety and efficacy results from a phase 1 study","volume":"8","author":"Budde","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B127","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13045-025-01764-5","article-title":"Updated data of cll1 car-t cell therapy in adult patients with relapsed\/refractory acute myeloid leukemia","volume":"18","author":"Zhang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/blood-2021-152692","article-title":"Phase 1\/1b safety study of prgn-3006 ultracar-t in patients with relapsed or refractory cd33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes","volume":"138","author":"Sallman","year":"2021","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1172\/jci162593","article-title":"Drug-regulated cd33-targeted car t cells control aml using clinically optimized rapamycin dosing","volume":"134","author":"Appelbaum","year":"2024","journal-title":"J Clin Invest"},{"key":"B130","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"Cd33 car t-cells (cd33cart) for children and young adults with relapsed\/refractory aml: dose-escalation results from a phase i\/ii multicenter trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.6518","article-title":"Phase i study of functionally enhanced cd33 car t cells in patients with relapsed or refractory acute myeloid leukemia","volume-title":"J Clin Oncol","author":"Pan","year":"2024"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01703-0","article-title":"Characteristics of anti-cll1 based car-t therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"B133","article-title":"Successful application of pd-1 knockdown cll-1 car-t therapy in two aml patients with post-transplant relapse and failure of anti-cd38 car-t cell treatment","volume":"12","author":"Ma","year":"2022","journal-title":"Am J Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-4543","article-title":"Anti-cll1 chimeric antigen receptor t-cell therapy in children with relapsed\/refractory acute myeloid leukemia","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B135","article-title":"A first-in-human phase 1, multicenter, open-label study of cb-012, a next-generation crispr-edited allogeneic anti-cll-1 car-t cell therapy for adults with relapsed\/refractory acute myeloid leukemia (amplify)","volume-title":"Blood","author":"Daver","year":"2022"},{"key":"B136","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40164-022-00318-6","article-title":"Cd7-directed car t-cell therapy: a potential immunotherapy strategy for relapsed\/refractory acute myeloid leukemia","volume":"11","author":"Cao","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024861","article-title":"Nanobody-based naturally selected cd7-targeted car-t therapy for acute myeloid leukemia","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02767-4","article-title":"Downregulation of mica\/micb improves cell persistence and clinical activity of nkg2dl car t-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia: acute myeloid leukemia","volume":"39","author":"Pollyea","year":"2025","journal-title":"Leukemia"},{"key":"B139","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-025-01708-z","article-title":"Cd19 car-t in relapsed t(8;21) aml: a single-center prospective phase ii clinical trial","volume":"18","author":"Yin","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1491341","article-title":"Utilization of donor cll-1 car-t cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated car t therapy resistance in aml","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat Med"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5412","article-title":"Second primary cancer after chimeric antigen receptor-t-cell therapy: a review","volume":"11","author":"Patel","year":"2025","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1837609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:04:47Z","timestamp":1784095487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1837609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":142,"alternative-id":["10.3389\/fimmu.2026.1837609"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1837609","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1837609"}}